We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Sorrento Therapeutics Announces Full Exercise of Over-Allotment Option PR Newswire SAN DIEGO, Oct. 25, 2013 SAN DIEGO, Oct. 25, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE...
Fri, Oct 25, 2013 12:00 - Sorrento Therapeutics, Inc. (SRNE: Nasdaq) - Venue Change - The symbol, SRNE, no longer trades on OTC Link. As of Fri, Oct 25, 2013, SRNE trades on Nasdaq. You may find...
Sorrento Therapeutics Acquires Clinical Stage Drug Candidate for Treatment of Chronic Pain PR Newswire SAN DIEGO, Oct. 10, 2013 SAN DIEGO, Oct. 10, 2013 /PRNewswire/ -- Sorrento Therapeutics...
Sorrento Therapeutics Announces a Presentation on Cynviloq™ at the AACR Conference on Advances in Ovarian Cancer Research: From Concept to Clinic PR Newswire SAN DIEGO, Sept. 16, 2013 SAN DIEGO...
Sorrento Therapeutics Secures Rights to Biomiga Diagnostics' Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy PR Newswire SAN DIEGO, Sept. 10, 2013 SAN...
Sorrento Therapeutics Completes IgDraSol Merger PR Newswire SAN DIEGO, Sept. 10, 2013 SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced...
Sorrento Therapeutics and IGDRASOL Proceed with Development of Cynviloq™ under 505(b)(2) Bioequivalence Regulatory Pathway Official Minutes from End-of-Phase 2 FDA Meeting Provide Clarity on Next...
Sorrento Therapeutics Announces Reverse Split of Common Stock PR Newswire SAN DIEGO, Aug. 1, 2013 SAN DIEGO, Aug. 1, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento...
Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th International Nanomedicine Conference in Sydney, Australia PR Newswire SAN DIEGO...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0006 | 28.5714285714 | 0.0021 | 0.004 | 0.0006 | 409828 | 0.00364569 | CS |
4 | 0.0021 | 350 | 0.0006 | 0.01 | 0.0006 | 267464 | 0.00339916 | CS |
12 | 0.0022 | 440 | 0.0005 | 0.0925 | 0.0005 | 188046 | 0.00517284 | CS |
26 | -0.0108 | -80 | 0.0135 | 0.0925 | 0.0002 | 145677 | 0.00753052 | CS |
52 | -0.0133 | -83.125 | 0.016 | 0.0925 | 0.0001 | 155986 | 0.01043147 | CS |
156 | -7.8573 | -99.965648855 | 7.86 | 7.86 | 0.0001 | 150607 | 0.01043147 | CS |
260 | -7.8573 | -99.965648855 | 7.86 | 7.86 | 0.0001 | 147554 | 0.01043147 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions